<?xml version="1.0" encoding="UTF-8" standalone="no"?><document setID="6c80bb38-e8db-4138-9f0d-dbbf9c673185"><labelDrug name="Remodulin"><Normalization><mmtx cui="C1101501" preferredWord="Remodulin" semType="phsu, lipd"/></Normalization></labelDrug><generic name="treprostinil"/><sentence id="Dailymed.6c80bb38-e8db-4138-9f0d-dbbf9c673185.s.1" text="REMODULIN (treprostinil) injection, solution" type="negative"><entity charOffset="11:23" id="Dailymed.6c80bb38-e8db-4138-9f0d-dbbf9c673185.s.1.e.0" text="treprostinil" type="Biomedical_Entity"><Normalization><mmtx cui="C1145760" phraseText="(treprostinil" preferredWord="Treprostinil" semType="eico, phsu"/><RxNorm RxCui="343048"/></Normalization></entity><entity charOffset="0:9" id="Dailymed.6c80bb38-e8db-4138-9f0d-dbbf9c673185.s.1.e.1" text="remodulin" type="Biomedical_Entity"><Normalization><mmtx cui="C1101501" phraseText="REMODULIN" preferredWord="Remodulin" semType="phsu, lipd"/><RxNorm RxCui="323640"/></Normalization></entity><pair ddi="false" e1="Dailymed.6c80bb38-e8db-4138-9f0d-dbbf9c673185.s.1.e.1" e2="Dailymed.6c80bb38-e8db-4138-9f0d-dbbf9c673185.s.1.e.0"/></sentence><sentence id="Dailymed.6c80bb38-e8db-4138-9f0d-dbbf9c673185.s.2" text="Remodulin (treprostinil) Injection is a sterile solution of treprostinil formulated for subcutaneous or intravenous administration." type="negative"><entity charOffset="11:23" id="Dailymed.6c80bb38-e8db-4138-9f0d-dbbf9c673185.s.2.e.0" text="treprostinil" type="Biomedical_Entity"><Normalization><mmtx cui="C1145760" phraseText="(treprostinil" preferredWord="Treprostinil" semType="eico, phsu"/><RxNorm RxCui="343048"/></Normalization></entity><entity charOffset="60:72" id="Dailymed.6c80bb38-e8db-4138-9f0d-dbbf9c673185.s.2.e.1" text="treprostinil" type="Biomedical_Entity"><Normalization><mmtx cui="C1145760" phraseText="a sterile solution of treprostinil" preferredWord="Treprostinil" semType="eico, phsu"/><RxNorm RxCui="343048"/></Normalization></entity><entity charOffset="0:9" id="Dailymed.6c80bb38-e8db-4138-9f0d-dbbf9c673185.s.2.e.2" text="remodulin" type="Biomedical_Entity"><Normalization><mmtx cui="C1101501" phraseText="Remodulin" preferredWord="Remodulin" semType="phsu, lipd"/><RxNorm RxCui="323640"/></Normalization></entity><pair ddi="false" e1="Dailymed.6c80bb38-e8db-4138-9f0d-dbbf9c673185.s.2.e.2" e2="Dailymed.6c80bb38-e8db-4138-9f0d-dbbf9c673185.s.2.e.0"/><pair ddi="false" e1="Dailymed.6c80bb38-e8db-4138-9f0d-dbbf9c673185.s.2.e.2" e2="Dailymed.6c80bb38-e8db-4138-9f0d-dbbf9c673185.s.2.e.1"/></sentence><sentence id="Dailymed.6c80bb38-e8db-4138-9f0d-dbbf9c673185.s.5" text="Remodulin is supplied in 20 mL vials containing 20, 50, 100, or 200 mg of treprostinil (1 mg/mL, 2.5 mg/mL, 5 mg/mL or 10 mg/mL). " type="negative"><entity charOffset="74:86" id="Dailymed.6c80bb38-e8db-4138-9f0d-dbbf9c673185.s.5.e.0" text="treprostinil" type="Biomedical_Entity"><Normalization><mmtx cui="C1145760" phraseText="200 mg of treprostinil" preferredWord="Treprostinil" semType="eico, phsu"/><RxNorm RxCui="343048"/></Normalization></entity><entity charOffset="0:9" id="Dailymed.6c80bb38-e8db-4138-9f0d-dbbf9c673185.s.5.e.1" text="remodulin" type="Biomedical_Entity"><Normalization><mmtx cui="C1101501" phraseText="Remodulin" preferredWord="Remodulin" semType="phsu, lipd"/><RxNorm RxCui="323640"/></Normalization></entity><pair ddi="false" e1="Dailymed.6c80bb38-e8db-4138-9f0d-dbbf9c673185.s.5.e.1" e2="Dailymed.6c80bb38-e8db-4138-9f0d-dbbf9c673185.s.5.e.0"/></sentence><sentence id="Dailymed.6c80bb38-e8db-4138-9f0d-dbbf9c673185.s.6" text="Remodulin can be administered as supplied or diluted for intravenous infusion with Sterile Water for Injection, 0.9% Sodium Chloride Injection, or Flolan  Sterile Diluent for Injection prior to administration." type="negative"><entity charOffset="112:142" id="Dailymed.6c80bb38-e8db-4138-9f0d-dbbf9c673185.s.6.e.0" text="0.9 sodium chloride injection" type="Biomedical_Entity"><Normalization><mmtx cui="C0980221" phraseText="0.9% Sodium Chloride Injection," preferredWord="Sodium Chloride 0.154 MEQ/ML Injectable Solution" semType="clnd"/><RxNorm RxCui="NA"/></Normalization></entity><entity charOffset="147:174" id="Dailymed.6c80bb38-e8db-4138-9f0d-dbbf9c673185.s.6.e.1" text="flolan sterile diluent for" type="Biomedical_Entity"><Normalization><mmtx cui="C0976408" phraseText="Flolan  Sterile Diluent for Injection" preferredWord="DILUENT,STERILE FOR FLOLAN" semType="clnd"/><RxNorm RxCui="114221"/></Normalization></entity><entity charOffset="0:9" id="Dailymed.6c80bb38-e8db-4138-9f0d-dbbf9c673185.s.6.e.2" text="remodulin" type="Biomedical_Entity"><Normalization><mmtx cui="C1101501" phraseText="Remodulin" preferredWord="Remodulin" semType="phsu, lipd"/><RxNorm RxCui="323640"/></Normalization></entity><entity charOffset="83:96" id="Dailymed.6c80bb38-e8db-4138-9f0d-dbbf9c673185.s.6.e.3" text="sterile water" type="Biomedical_Entity"><Normalization><mmtx cui="C0359299" phraseText="with Sterile Water" preferredWord="sterile water" semType="inch, phsu"/><RxNorm RxCui="107129"/></Normalization></entity><pair ddi="false" e1="Dailymed.6c80bb38-e8db-4138-9f0d-dbbf9c673185.s.6.e.0" e2="Dailymed.6c80bb38-e8db-4138-9f0d-dbbf9c673185.s.6.e.1"/><pair ddi="false" e1="Dailymed.6c80bb38-e8db-4138-9f0d-dbbf9c673185.s.6.e.2" e2="Dailymed.6c80bb38-e8db-4138-9f0d-dbbf9c673185.s.6.e.0"/><pair ddi="false" e1="Dailymed.6c80bb38-e8db-4138-9f0d-dbbf9c673185.s.6.e.3" e2="Dailymed.6c80bb38-e8db-4138-9f0d-dbbf9c673185.s.6.e.0"/><pair ddi="false" e1="Dailymed.6c80bb38-e8db-4138-9f0d-dbbf9c673185.s.6.e.2" e2="Dailymed.6c80bb38-e8db-4138-9f0d-dbbf9c673185.s.6.e.1"/><pair ddi="false" e1="Dailymed.6c80bb38-e8db-4138-9f0d-dbbf9c673185.s.6.e.3" e2="Dailymed.6c80bb38-e8db-4138-9f0d-dbbf9c673185.s.6.e.1"/><pair ddi="false" e1="Dailymed.6c80bb38-e8db-4138-9f0d-dbbf9c673185.s.6.e.2" e2="Dailymed.6c80bb38-e8db-4138-9f0d-dbbf9c673185.s.6.e.3"/></sentence><sentence id="Dailymed.6c80bb38-e8db-4138-9f0d-dbbf9c673185.s.36" text="Remodulin must be diluted with either Sterile Water for Injection, 0.9% Sodium Chloride Injection, or Flolan Sterile Diluent for Injection and is administered intravenously by continuous infusion, via a surgically placed indwelling central venous catheter, using an infusion pump designed for intravenous drug delivery. " type="negative"><entity charOffset="293:309" id="Dailymed.6c80bb38-e8db-4138-9f0d-dbbf9c673185.s.36.e.0" text="intravenous drug" type="Biomedical_Entity"><Normalization><mmtx cui="C0683092" phraseText="designed for intravenous drug delivery." preferredWord="injected substance" semType="phsu"/><RxNorm RxCui="NA"/></Normalization></entity><entity charOffset="67:97" id="Dailymed.6c80bb38-e8db-4138-9f0d-dbbf9c673185.s.36.e.1" text="0.9 sodium chloride injection" type="Biomedical_Entity"><Normalization><mmtx cui="C0980221" phraseText="0.9% Sodium Chloride Injection," preferredWord="Sodium Chloride 0.154 MEQ/ML Injectable Solution" semType="clnd"/><RxNorm RxCui="NA"/></Normalization></entity><entity charOffset="102:128" id="Dailymed.6c80bb38-e8db-4138-9f0d-dbbf9c673185.s.36.e.2" text="flolan sterile diluent for" type="Biomedical_Entity"><Normalization><mmtx cui="C0976408" phraseText="Flolan Sterile Diluent for Injection" preferredWord="DILUENT,STERILE FOR FLOLAN" semType="clnd"/><RxNorm RxCui="114221"/></Normalization></entity><entity charOffset="0:9" id="Dailymed.6c80bb38-e8db-4138-9f0d-dbbf9c673185.s.36.e.3" text="remodulin" type="Biomedical_Entity"><Normalization><mmtx cui="C1101501" phraseText="Remodulin" preferredWord="Remodulin" semType="phsu, lipd"/><RxNorm RxCui="323640"/></Normalization></entity><entity charOffset="38:51" id="Dailymed.6c80bb38-e8db-4138-9f0d-dbbf9c673185.s.36.e.4" text="sterile water" type="Biomedical_Entity"><Normalization><mmtx cui="C0359299" phraseText="diluted with either Sterile Water" preferredWord="sterile water" semType="inch, phsu"/><RxNorm RxCui="107129"/></Normalization></entity><pair ddi="false" e1="Dailymed.6c80bb38-e8db-4138-9f0d-dbbf9c673185.s.36.e.1" e2="Dailymed.6c80bb38-e8db-4138-9f0d-dbbf9c673185.s.36.e.0"/><pair ddi="false" e1="Dailymed.6c80bb38-e8db-4138-9f0d-dbbf9c673185.s.36.e.2" e2="Dailymed.6c80bb38-e8db-4138-9f0d-dbbf9c673185.s.36.e.0"/><pair ddi="false" e1="Dailymed.6c80bb38-e8db-4138-9f0d-dbbf9c673185.s.36.e.3" e2="Dailymed.6c80bb38-e8db-4138-9f0d-dbbf9c673185.s.36.e.0"/><pair ddi="false" e1="Dailymed.6c80bb38-e8db-4138-9f0d-dbbf9c673185.s.36.e.4" e2="Dailymed.6c80bb38-e8db-4138-9f0d-dbbf9c673185.s.36.e.0"/><pair ddi="false" e1="Dailymed.6c80bb38-e8db-4138-9f0d-dbbf9c673185.s.36.e.1" e2="Dailymed.6c80bb38-e8db-4138-9f0d-dbbf9c673185.s.36.e.2"/><pair ddi="false" e1="Dailymed.6c80bb38-e8db-4138-9f0d-dbbf9c673185.s.36.e.3" e2="Dailymed.6c80bb38-e8db-4138-9f0d-dbbf9c673185.s.36.e.1"/><pair ddi="false" e1="Dailymed.6c80bb38-e8db-4138-9f0d-dbbf9c673185.s.36.e.4" e2="Dailymed.6c80bb38-e8db-4138-9f0d-dbbf9c673185.s.36.e.1"/><pair ddi="false" e1="Dailymed.6c80bb38-e8db-4138-9f0d-dbbf9c673185.s.36.e.3" e2="Dailymed.6c80bb38-e8db-4138-9f0d-dbbf9c673185.s.36.e.2"/><pair ddi="false" e1="Dailymed.6c80bb38-e8db-4138-9f0d-dbbf9c673185.s.36.e.4" e2="Dailymed.6c80bb38-e8db-4138-9f0d-dbbf9c673185.s.36.e.2"/><pair ddi="false" e1="Dailymed.6c80bb38-e8db-4138-9f0d-dbbf9c673185.s.36.e.3" e2="Dailymed.6c80bb38-e8db-4138-9f0d-dbbf9c673185.s.36.e.4"/></sentence><sentence id="Dailymed.6c80bb38-e8db-4138-9f0d-dbbf9c673185.s.44" text="Transition from Flolan to Remodulin is accomplished by initiating the infusion of Remodulin and increasing it, while simultaneously reducing the dose of intravenous Flolan. " type="negative"><entity charOffset="82:91" id="Dailymed.6c80bb38-e8db-4138-9f0d-dbbf9c673185.s.44.e.0" text="remodulin" type="Biomedical_Entity"><Normalization><mmtx cui="C1101501" phraseText="the infusion of Remodulin" preferredWord="Remodulin" semType="phsu, lipd"/><RxNorm RxCui="323640"/></Normalization></entity><entity charOffset="16:22" id="Dailymed.6c80bb38-e8db-4138-9f0d-dbbf9c673185.s.44.e.1" text="flolan" type="Biomedical_Entity"><Normalization><mmtx cui="C0376357" phraseText="Transition from Flolan" preferredWord="Flolan" semType="eico, phsu"/><RxNorm RxCui="114221"/></Normalization></entity><entity charOffset="26:35" id="Dailymed.6c80bb38-e8db-4138-9f0d-dbbf9c673185.s.44.e.2" text="remodulin" type="Biomedical_Entity"><Normalization><mmtx cui="C1101501" phraseText="to Remodulin" preferredWord="Remodulin" semType="phsu, lipd"/><RxNorm RxCui="323640"/></Normalization></entity><entity charOffset="165:171" id="Dailymed.6c80bb38-e8db-4138-9f0d-dbbf9c673185.s.44.e.3" text="flolan" type="Biomedical_Entity"><Normalization><mmtx cui="C0376357" phraseText="the dose of intravenous Flolan." preferredWord="Flolan" semType="eico, phsu"/><RxNorm RxCui="114221"/></Normalization></entity><pair ddi="false" e1="Dailymed.6c80bb38-e8db-4138-9f0d-dbbf9c673185.s.44.e.1" e2="Dailymed.6c80bb38-e8db-4138-9f0d-dbbf9c673185.s.44.e.0"/><pair ddi="false" e1="Dailymed.6c80bb38-e8db-4138-9f0d-dbbf9c673185.s.44.e.0" e2="Dailymed.6c80bb38-e8db-4138-9f0d-dbbf9c673185.s.44.e.3"/><pair ddi="false" e1="Dailymed.6c80bb38-e8db-4138-9f0d-dbbf9c673185.s.44.e.1" e2="Dailymed.6c80bb38-e8db-4138-9f0d-dbbf9c673185.s.44.e.2"/><pair ddi="false" e1="Dailymed.6c80bb38-e8db-4138-9f0d-dbbf9c673185.s.44.e.2" e2="Dailymed.6c80bb38-e8db-4138-9f0d-dbbf9c673185.s.44.e.3"/></sentence><sentence id="Dailymed.6c80bb38-e8db-4138-9f0d-dbbf9c673185.s.46" text="During the transition, Remodulin is initiated at a recommended dose of 10% of the current Flolan dose, and then escalated as the Flolan dose is decreased (see Table 1 for recommended dose titrations)." type="negative"><entity charOffset="90:96" id="Dailymed.6c80bb38-e8db-4138-9f0d-dbbf9c673185.s.46.e.0" text="flolan" type="Biomedical_Entity"><Normalization><mmtx cui="C0376357" phraseText="initiated at a recommended dose of 10% of the current Flolan dose," preferredWord="Flolan" semType="eico, phsu"/><RxNorm RxCui="114221"/></Normalization></entity><entity charOffset="129:135" id="Dailymed.6c80bb38-e8db-4138-9f0d-dbbf9c673185.s.46.e.1" text="flolan" type="Biomedical_Entity"><Normalization><mmtx cui="C0376357" phraseText="escalated as the Flolan dose" preferredWord="Flolan" semType="eico, phsu"/><RxNorm RxCui="114221"/></Normalization></entity><entity charOffset="23:32" id="Dailymed.6c80bb38-e8db-4138-9f0d-dbbf9c673185.s.46.e.2" text="remodulin" type="Biomedical_Entity"><Normalization><mmtx cui="C1101501" phraseText="Remodulin" preferredWord="Remodulin" semType="phsu, lipd"/><RxNorm RxCui="323640"/></Normalization></entity><pair ddi="false" e1="Dailymed.6c80bb38-e8db-4138-9f0d-dbbf9c673185.s.46.e.2" e2="Dailymed.6c80bb38-e8db-4138-9f0d-dbbf9c673185.s.46.e.0"/><pair ddi="false" e1="Dailymed.6c80bb38-e8db-4138-9f0d-dbbf9c673185.s.46.e.2" e2="Dailymed.6c80bb38-e8db-4138-9f0d-dbbf9c673185.s.46.e.1"/></sentence><sentence id="Dailymed.6c80bb38-e8db-4138-9f0d-dbbf9c673185.s.47" text="Patients are individually titrated to a dose that allows transition from Flolan therapy to Remodulin while balancing prostacyclin-limiting adverse events. " type="negative"><entity charOffset="117:129" id="Dailymed.6c80bb38-e8db-4138-9f0d-dbbf9c673185.s.47.e.0" text="prostacyclin" type="Biomedical_Entity"><Normalization><mmtx cui="C0033567" phraseText="balancing prostacyclin-" preferredWord="Epoprostenol" semType="eico, bacs, phsu"/><RxNorm RxCui="8814"/></Normalization></entity><entity charOffset="91:100" id="Dailymed.6c80bb38-e8db-4138-9f0d-dbbf9c673185.s.47.e.1" text="remodulin" type="Biomedical_Entity"><Normalization><mmtx cui="C1101501" phraseText="to Remodulin" preferredWord="Remodulin" semType="phsu, lipd"/><RxNorm RxCui="323640"/></Normalization></entity><entity charOffset="73:79" id="Dailymed.6c80bb38-e8db-4138-9f0d-dbbf9c673185.s.47.e.2" text="flolan" type="Biomedical_Entity"><Normalization><mmtx cui="C0376357" phraseText="transition from Flolan therapy" preferredWord="Flolan" semType="eico, phsu"/><RxNorm RxCui="114221"/></Normalization></entity><pair ddi="false" e1="Dailymed.6c80bb38-e8db-4138-9f0d-dbbf9c673185.s.47.e.1" e2="Dailymed.6c80bb38-e8db-4138-9f0d-dbbf9c673185.s.47.e.0"/><pair ddi="false" e1="Dailymed.6c80bb38-e8db-4138-9f0d-dbbf9c673185.s.47.e.2" e2="Dailymed.6c80bb38-e8db-4138-9f0d-dbbf9c673185.s.47.e.0"/><pair ddi="false" e1="Dailymed.6c80bb38-e8db-4138-9f0d-dbbf9c673185.s.47.e.2" e2="Dailymed.6c80bb38-e8db-4138-9f0d-dbbf9c673185.s.47.e.1"/></sentence><sentence id="Dailymed.6c80bb38-e8db-4138-9f0d-dbbf9c673185.s.49" text="Side effects normally associated with prostacyclin and prostacyclin analogs are to be first treated by decreasing the dose of Flolan." type="negative"><entity charOffset="38:50" id="Dailymed.6c80bb38-e8db-4138-9f0d-dbbf9c673185.s.49.e.0" text="prostacyclin" type="Biomedical_Entity"><Normalization><mmtx cui="C0033567" phraseText="associated with prostacyclin" preferredWord="Epoprostenol" semType="eico, bacs, phsu"/><RxNorm RxCui="8814"/></Normalization></entity><entity charOffset="126:132" id="Dailymed.6c80bb38-e8db-4138-9f0d-dbbf9c673185.s.49.e.1" text="flolan" type="Biomedical_Entity"><Normalization><mmtx cui="C0376357" phraseText="the dose of Flolan." preferredWord="Flolan" semType="eico, phsu"/><RxNorm RxCui="114221"/></Normalization></entity><entity charOffset="55:67" id="Dailymed.6c80bb38-e8db-4138-9f0d-dbbf9c673185.s.49.e.2" text="prostacyclin" type="Biomedical_Entity"><Normalization><mmtx cui="C0033567" phraseText="prostacyclin analogs" preferredWord="Epoprostenol" semType="eico, bacs, phsu"/><RxNorm RxCui="8814"/></Normalization></entity><pair ddi="false" e1="Dailymed.6c80bb38-e8db-4138-9f0d-dbbf9c673185.s.49.e.0" e2="Dailymed.6c80bb38-e8db-4138-9f0d-dbbf9c673185.s.49.e.1"/><pair ddi="false" e1="Dailymed.6c80bb38-e8db-4138-9f0d-dbbf9c673185.s.49.e.2" e2="Dailymed.6c80bb38-e8db-4138-9f0d-dbbf9c673185.s.49.e.1"/></sentence><sentence id="Dailymed.6c80bb38-e8db-4138-9f0d-dbbf9c673185.s.54" text="Chronic intravenous infusions of Remodulin are delivered using an indwelling central venous catheter. " type="negative"><entity charOffset="47:56" id="Dailymed.6c80bb38-e8db-4138-9f0d-dbbf9c673185.s.54.e.0" text="delivered" type="Biomedical_Entity"><Normalization><mmtx cui="C1874964" phraseText="delivered" preferredWord="DELIVER (Dietary Supplement)" semType="phsu"/><RxNorm RxCui="693491"/></Normalization></entity><entity charOffset="33:42" id="Dailymed.6c80bb38-e8db-4138-9f0d-dbbf9c673185.s.54.e.1" text="remodulin" type="Biomedical_Entity"><Normalization><mmtx cui="C1101501" phraseText="Chronic intravenous infusions of Remodulin" preferredWord="Remodulin" semType="phsu, lipd"/><RxNorm RxCui="323640"/></Normalization></entity><pair ddi="false" e1="Dailymed.6c80bb38-e8db-4138-9f0d-dbbf9c673185.s.54.e.1" e2="Dailymed.6c80bb38-e8db-4138-9f0d-dbbf9c673185.s.54.e.0"/></sentence><sentence id="Dailymed.6c80bb38-e8db-4138-9f0d-dbbf9c673185.s.61" text="Remodulin is a potent pulmonary and systemic vasodilator. " type="negative"><entity charOffset="0:9" id="Dailymed.6c80bb38-e8db-4138-9f0d-dbbf9c673185.s.61.e.0" text="remodulin" type="Biomedical_Entity"><Normalization><mmtx cui="C1101501" phraseText="Remodulin" preferredWord="Remodulin" semType="phsu, lipd"/><RxNorm RxCui="323640"/></Normalization></entity><entity charOffset="45:56" id="Dailymed.6c80bb38-e8db-4138-9f0d-dbbf9c673185.s.61.e.1" text="vasodilator" type="Biomedical_Entity"><Normalization><mmtx cui="C0042402" phraseText="systemic vasodilator." preferredWord="Vasodilator Agents" semType="phsu"/><RxNorm RxCui="11146"/></Normalization></entity><pair ddi="false" e1="Dailymed.6c80bb38-e8db-4138-9f0d-dbbf9c673185.s.61.e.0" e2="Dailymed.6c80bb38-e8db-4138-9f0d-dbbf9c673185.s.61.e.1"/></sentence><sentence biomedicalEntities="3" id="Dailymed.6c80bb38-e8db-4138-9f0d-dbbf9c673185.s.71" lineNumber="83" text="Co-administration of a cytochrome P450 (CYP) 2C8 enzyme inhibitor (e.g., gemfibrozil) may increase exposure (both Cmax and AUC) to treprostinil. " type="regular"><entity charOffset="23:65" id="Dailymed.6c80bb38-e8db-4138-9f0d-dbbf9c673185.s.71.e.0" text="cytochrome P450 (CYP) 2C8 enzyme inhibitor" type="Drug_Class"><Normalization><mmtx cui="C0014432" phraseText="Co-administration of a cytochrome P450 (CYP) 2C8 enzyme inhibitor" preferredWord="Enzyme Inhibitors" semType="phsu"/><mmtx cui="C0919438" phraseText="Co-administration of a cytochrome P450 (CYP) 2C8 enzyme inhibitor" preferredWord="Enzyme Inhibitor Drugs" semType="phsu"/><RxNorm RxCui="3065"/></Normalization></entity><entity charOffset="73:84" id="Dailymed.6c80bb38-e8db-4138-9f0d-dbbf9c673185.s.71.e.1" text="gemfibrozil" type="Drug"><Normalization><mmtx cui="C0017245" phraseText="gemfibrozil" preferredWord="Gemfibrozil" semType="phsu, lipd"/><RxNorm RxCui="4719"/></Normalization></entity><entity charOffset="90:107|114:118" id="Dailymed.6c80bb38-e8db-4138-9f0d-dbbf9c673185.s.71.e.3" text="increase exposure Cmax" type="Increase_Interaction"/><entity charOffset="131:143" id="Dailymed.6c80bb38-e8db-4138-9f0d-dbbf9c673185.s.71.e.5" text="treprostinil" type="Drug"><Normalization><mmtx cui="C1145760" phraseText="AUC) to treprostinil." preferredWord="Treprostinil" semType="eico, phsu"/><RxNorm RxCui="343048"/></Normalization></entity><entity charOffset="90:107|123:126" id="Dailymed.6c80bb38-e8db-4138-9f0d-dbbf9c673185.s.71.e.6" text="increase exposure AUC" type="Increase_Interaction"/><drugClassMembership drug="Dailymed.6c80bb38-e8db-4138-9f0d-dbbf9c673185.s.71.e.1" drugClass="Dailymed.6c80bb38-e8db-4138-9f0d-dbbf9c673185.s.71.e.0"/><drugInteraction id="Dailymed.6c80bb38-e8db-4138-9f0d-dbbf9c673185.s.71.ddi.1"><interaction trigger="Dailymed.6c80bb38-e8db-4138-9f0d-dbbf9c673185.s.71.e.3"><relations><relation type="hasObject"><entity id="Dailymed.6c80bb38-e8db-4138-9f0d-dbbf9c673185.s.71.e.5"/></relation><relation type="hasPrecipitant"><entity id="Dailymed.6c80bb38-e8db-4138-9f0d-dbbf9c673185.s.71.e.0"/></relation></relations></interaction></drugInteraction><drugInteraction id="Dailymed.6c80bb38-e8db-4138-9f0d-dbbf9c673185.s.71.ddi.2"><interaction trigger="Dailymed.6c80bb38-e8db-4138-9f0d-dbbf9c673185.s.71.e.6"><relations><relation type="hasObject"><entity id="Dailymed.6c80bb38-e8db-4138-9f0d-dbbf9c673185.s.71.e.5"/></relation><relation type="hasPrecipitant"><entity id="Dailymed.6c80bb38-e8db-4138-9f0d-dbbf9c673185.s.71.e.0"/></relation></relations></interaction></drugInteraction><pair ddi="true" e1="Dailymed.6c80bb38-e8db-4138-9f0d-dbbf9c673185.s.71.e.0" e2="Dailymed.6c80bb38-e8db-4138-9f0d-dbbf9c673185.s.71.e.5" trigger="Dailymed.6c80bb38-e8db-4138-9f0d-dbbf9c673185.s.71.e.3" type="Increase_Interaction"/></sentence><sentence biomedicalEntities="3" id="Dailymed.6c80bb38-e8db-4138-9f0d-dbbf9c673185.s.72" lineNumber="83" text="Co-administration of a CYP2C8 enzyme inducer (e.g., rifampin) may decrease exposure to treprostinil. " type="regular"><entity charOffset="23:44" id="Dailymed.6c80bb38-e8db-4138-9f0d-dbbf9c673185.s.72.e.0" text="CYP2C8 enzyme inducer" type="Drug_Class"><Normalization><RxNorm RxCui="687277"/></Normalization></entity><entity charOffset="52:60" id="Dailymed.6c80bb38-e8db-4138-9f0d-dbbf9c673185.s.72.e.1" text="rifampin" type="Drug"><Normalization><mmtx cui="C0035608" phraseText="rifampin" preferredWord="Rifampin" semType="orch, antb"/><RxNorm RxCui="9384"/></Normalization></entity><entity charOffset="87:99" id="Dailymed.6c80bb38-e8db-4138-9f0d-dbbf9c673185.s.72.e.3" text="treprostinil" type="Drug"><Normalization><mmtx cui="C1145760" phraseText="exposure to treprostinil." preferredWord="Treprostinil" semType="eico, phsu"/><RxNorm RxCui="343048"/></Normalization></entity><entity charOffset="66:83" id="Dailymed.6c80bb38-e8db-4138-9f0d-dbbf9c673185.s.72.e.4" text="decrease exposure" type="Decrease_Interaction"/><drugClassMembership drug="Dailymed.6c80bb38-e8db-4138-9f0d-dbbf9c673185.s.72.e.1" drugClass="Dailymed.6c80bb38-e8db-4138-9f0d-dbbf9c673185.s.72.e.0"/><drugInteraction id="Dailymed.6c80bb38-e8db-4138-9f0d-dbbf9c673185.s.72.ddi.1"><interaction trigger="Dailymed.6c80bb38-e8db-4138-9f0d-dbbf9c673185.s.72.e.4"><relations><relation type="hasPrecipitant"><entity id="Dailymed.6c80bb38-e8db-4138-9f0d-dbbf9c673185.s.72.e.0"/></relation><relation type="hasObject"><entity id="Dailymed.6c80bb38-e8db-4138-9f0d-dbbf9c673185.s.72.e.3"/></relation></relations></interaction></drugInteraction><pair ddi="true" e1="Dailymed.6c80bb38-e8db-4138-9f0d-dbbf9c673185.s.72.e.0" e2="Dailymed.6c80bb38-e8db-4138-9f0d-dbbf9c673185.s.72.e.3" trigger="Dailymed.6c80bb38-e8db-4138-9f0d-dbbf9c673185.s.72.e.4" type="Decrease_Interaction"/></sentence><sentence id="Dailymed.6c80bb38-e8db-4138-9f0d-dbbf9c673185.s.75" text="Pharmacokinetic/pharmacodynamic interaction studies have been conducted with treprostinil administered subcutaneously (Remodulin) and orally (treprostinil diethanolamine)." type="negative"><entity charOffset="119:128" id="Dailymed.6c80bb38-e8db-4138-9f0d-dbbf9c673185.s.75.e.0" text="remodulin" type="Biomedical_Entity"><Normalization><mmtx cui="C1101501" phraseText="(Remodulin" preferredWord="Remodulin" semType="phsu, lipd"/><RxNorm RxCui="323640"/></Normalization></entity><entity charOffset="77:89" id="Dailymed.6c80bb38-e8db-4138-9f0d-dbbf9c673185.s.75.e.1" text="treprostinil" type="Biomedical_Entity"><Normalization><mmtx cui="C1145760" phraseText="conducted with treprostinil" preferredWord="Treprostinil" semType="eico, phsu"/><RxNorm RxCui="343048"/></Normalization></entity><entity charOffset="155:169" id="Dailymed.6c80bb38-e8db-4138-9f0d-dbbf9c673185.s.75.e.2" text="diethanolamine" type="Biomedical_Entity"><Normalization><mmtx cui="C0057919" phraseText="(treprostinil diethanolamine" preferredWord="diethanolamine" semType="phsu, orch"/><RxNorm RxCui="1362911"/></Normalization></entity><entity charOffset="142:154" id="Dailymed.6c80bb38-e8db-4138-9f0d-dbbf9c673185.s.75.e.3" text="treprostinil" type="Biomedical_Entity"><Normalization><mmtx cui="C1145760" phraseText="(treprostinil diethanolamine" preferredWord="Treprostinil" semType="eico, phsu"/><RxNorm RxCui="343048"/></Normalization></entity><pair ddi="false" e1="Dailymed.6c80bb38-e8db-4138-9f0d-dbbf9c673185.s.75.e.1" e2="Dailymed.6c80bb38-e8db-4138-9f0d-dbbf9c673185.s.75.e.0"/><pair ddi="false" e1="Dailymed.6c80bb38-e8db-4138-9f0d-dbbf9c673185.s.75.e.0" e2="Dailymed.6c80bb38-e8db-4138-9f0d-dbbf9c673185.s.75.e.2"/><pair ddi="false" e1="Dailymed.6c80bb38-e8db-4138-9f0d-dbbf9c673185.s.75.e.0" e2="Dailymed.6c80bb38-e8db-4138-9f0d-dbbf9c673185.s.75.e.3"/><pair ddi="false" e1="Dailymed.6c80bb38-e8db-4138-9f0d-dbbf9c673185.s.75.e.1" e2="Dailymed.6c80bb38-e8db-4138-9f0d-dbbf9c673185.s.75.e.2"/><pair ddi="false" e1="Dailymed.6c80bb38-e8db-4138-9f0d-dbbf9c673185.s.75.e.3" e2="Dailymed.6c80bb38-e8db-4138-9f0d-dbbf9c673185.s.75.e.2"/></sentence><sentence id="Dailymed.6c80bb38-e8db-4138-9f0d-dbbf9c673185.s.77" text="7.1 Antihypertensive Agents or Other Vasodilators" type="negative"><entity charOffset="37:49" id="Dailymed.6c80bb38-e8db-4138-9f0d-dbbf9c673185.s.77.e.0" text="vasodilators" type="Biomedical_Entity"><Normalization><mmtx cui="C0042402" phraseText="Other Vasodilators" preferredWord="Vasodilator Agents" semType="phsu"/><RxNorm RxCui="11146"/></Normalization></entity><entity charOffset="4:27" id="Dailymed.6c80bb38-e8db-4138-9f0d-dbbf9c673185.s.77.e.1" text="antihypertensive agents" type="Biomedical_Entity"><Normalization><mmtx cui="C0003364" phraseText="7.1 Antihypertensive Agents" preferredWord="Antihypertensive Agents" semType="phsu"/><RxNorm RxCui="968"/></Normalization></entity><pair ddi="false" e1="Dailymed.6c80bb38-e8db-4138-9f0d-dbbf9c673185.s.77.e.1" e2="Dailymed.6c80bb38-e8db-4138-9f0d-dbbf9c673185.s.77.e.0"/></sentence><sentence biomedicalEntities="4" id="Dailymed.6c80bb38-e8db-4138-9f0d-dbbf9c673185.s.78" lineNumber="93" text="Concomitant administration of Remodulin with diuretics, antihypertensive agents or other vasodilators may increase the risk of symptomatic hypotension." type="regular"><entity charOffset="30:39" id="Dailymed.6c80bb38-e8db-4138-9f0d-dbbf9c673185.s.78.e.0" text="Remodulin" type="Drug"><Normalization><mmtx cui="C1101501" phraseText="Concomitant administration of Remodulin" preferredWord="Remodulin" semType="phsu, lipd"/><RxNorm RxCui="323640"/></Normalization></entity><entity charOffset="45:54" id="Dailymed.6c80bb38-e8db-4138-9f0d-dbbf9c673185.s.78.e.1" text="diuretics" type="Drug_Class"><Normalization><mmtx cui="C0012798" phraseText="with diuretics," preferredWord="Diuretics" semType="phsu"/><RxNorm RxCui="3567"/></Normalization></entity><entity charOffset="56:79" id="Dailymed.6c80bb38-e8db-4138-9f0d-dbbf9c673185.s.78.e.2" text="antihypertensive agents" type="Drug_Class"><Normalization><mmtx cui="C0003364" phraseText="antihypertensive agents" preferredWord="Antihypertensive Agents" semType="phsu"/><RxNorm RxCui="968"/></Normalization></entity><entity charOffset="89:101" id="Dailymed.6c80bb38-e8db-4138-9f0d-dbbf9c673185.s.78.e.3" text="vasodilators" type="Drug_Class"><Normalization><mmtx cui="C0042402" phraseText="other vasodilators" preferredWord="Vasodilator Agents" semType="phsu"/><RxNorm RxCui="11146"/></Normalization></entity><entity charOffset="127:150" id="Dailymed.6c80bb38-e8db-4138-9f0d-dbbf9c673185.s.78.e.4" text="symptomatic hypotension" type="Specific_Interaction"/><drugInteraction id="Dailymed.6c80bb38-e8db-4138-9f0d-dbbf9c673185.s.78.ddi.1"><interaction trigger="Dailymed.6c80bb38-e8db-4138-9f0d-dbbf9c673185.s.78.e.4"><relations><relation type="hasPrecipitant"><entity id="Dailymed.6c80bb38-e8db-4138-9f0d-dbbf9c673185.s.78.e.1"/></relation><relation type="hasPrecipitant"><entity id="Dailymed.6c80bb38-e8db-4138-9f0d-dbbf9c673185.s.78.e.3"/></relation><relation type="hasPrecipitant"><entity id="Dailymed.6c80bb38-e8db-4138-9f0d-dbbf9c673185.s.78.e.2"/></relation><relation type="hasObject"><entity id="Dailymed.6c80bb38-e8db-4138-9f0d-dbbf9c673185.s.78.e.0"/></relation></relations></interaction></drugInteraction><pair ddi="true" e1="Dailymed.6c80bb38-e8db-4138-9f0d-dbbf9c673185.s.78.e.0" e2="Dailymed.6c80bb38-e8db-4138-9f0d-dbbf9c673185.s.78.e.1" trigger="Dailymed.6c80bb38-e8db-4138-9f0d-dbbf9c673185.s.78.e.4" type="Specific_Interaction"/><pair ddi="true" e1="Dailymed.6c80bb38-e8db-4138-9f0d-dbbf9c673185.s.78.e.0" e2="Dailymed.6c80bb38-e8db-4138-9f0d-dbbf9c673185.s.78.e.3" trigger="Dailymed.6c80bb38-e8db-4138-9f0d-dbbf9c673185.s.78.e.4" type="Specific_Interaction"/><pair ddi="true" e1="Dailymed.6c80bb38-e8db-4138-9f0d-dbbf9c673185.s.78.e.0" e2="Dailymed.6c80bb38-e8db-4138-9f0d-dbbf9c673185.s.78.e.2" trigger="Dailymed.6c80bb38-e8db-4138-9f0d-dbbf9c673185.s.78.e.4" type="Specific_Interaction"/><pair ddi="false" e1="Dailymed.6c80bb38-e8db-4138-9f0d-dbbf9c673185.s.78.e.1" e2="Dailymed.6c80bb38-e8db-4138-9f0d-dbbf9c673185.s.78.e.3"/><pair ddi="false" e1="Dailymed.6c80bb38-e8db-4138-9f0d-dbbf9c673185.s.78.e.1" e2="Dailymed.6c80bb38-e8db-4138-9f0d-dbbf9c673185.s.78.e.2"/><pair ddi="false" e1="Dailymed.6c80bb38-e8db-4138-9f0d-dbbf9c673185.s.78.e.2" e2="Dailymed.6c80bb38-e8db-4138-9f0d-dbbf9c673185.s.78.e.3"/></sentence><sentence biomedicalEntities="2" id="Dailymed.6c80bb38-e8db-4138-9f0d-dbbf9c673185.s.80" lineNumber="97" text="Since treprostinil inhibits platelet aggregation, there may be an increased risk of bleeding, particularly among patients receiving anticoagulants." type="regular"><entity charOffset="132:146" id="Dailymed.6c80bb38-e8db-4138-9f0d-dbbf9c673185.s.80.e.0" text="anticoagulants" type="Drug_Class"><Normalization><mmtx cui="C0003280" phraseText="anticoagulants." preferredWord="Anticoagulants" semType="phsu"/><RxNorm RxCui="923"/></Normalization></entity><entity charOffset="6:18" id="Dailymed.6c80bb38-e8db-4138-9f0d-dbbf9c673185.s.80.e.1" text="treprostinil" type="Drug"><Normalization><mmtx cui="C1145760" phraseText="treprostinil" preferredWord="Treprostinil" semType="eico, phsu"/><RxNorm RxCui="343048"/></Normalization></entity><entity charOffset="66:92" id="Dailymed.6c80bb38-e8db-4138-9f0d-dbbf9c673185.s.80.e.2" text="increased risk of bleeding" type="Specific_Interaction"/><drugInteraction id="Dailymed.6c80bb38-e8db-4138-9f0d-dbbf9c673185.s.80.ddi.1"><interaction trigger="Dailymed.6c80bb38-e8db-4138-9f0d-dbbf9c673185.s.80.e.2"><relations><relation type="hasObject"><entity id="Dailymed.6c80bb38-e8db-4138-9f0d-dbbf9c673185.s.80.e.1"/></relation><relation type="hasPrecipitant"><entity id="Dailymed.6c80bb38-e8db-4138-9f0d-dbbf9c673185.s.80.e.0"/></relation></relations></interaction></drugInteraction><pair ddi="true" e1="Dailymed.6c80bb38-e8db-4138-9f0d-dbbf9c673185.s.80.e.1" e2="Dailymed.6c80bb38-e8db-4138-9f0d-dbbf9c673185.s.80.e.0" trigger="Dailymed.6c80bb38-e8db-4138-9f0d-dbbf9c673185.s.80.e.2" type="Specific_Interaction"/></sentence><sentence id="Dailymed.6c80bb38-e8db-4138-9f0d-dbbf9c673185.s.83" text="In a human pharmacokinetic study conducted with bosentan (250 mg/day) and an oral formulation of treprostinil (treprostinil diethanolamine), no pharmacokinetic interactions between treprostinil and bosentan were observed." type="negative"><entity charOffset="48:56" id="Dailymed.6c80bb38-e8db-4138-9f0d-dbbf9c673185.s.83.e.0" text="bosentan" type="Biomedical_Entity"><Normalization><mmtx cui="C0252643" phraseText="conducted with bosentan" preferredWord="bosentan" semType="phsu, orch"/><RxNorm RxCui="75207"/></Normalization></entity><entity charOffset="111:123" id="Dailymed.6c80bb38-e8db-4138-9f0d-dbbf9c673185.s.83.e.1" text="treprostinil" type="Biomedical_Entity"><Normalization><mmtx cui="C1145760" phraseText="(treprostinil diethanolamine" preferredWord="Treprostinil" semType="eico, phsu"/><RxNorm RxCui="343048"/></Normalization></entity><entity charOffset="181:193" id="Dailymed.6c80bb38-e8db-4138-9f0d-dbbf9c673185.s.83.e.2" text="treprostinil" type="Biomedical_Entity"><Normalization><mmtx cui="C1145760" phraseText="no pharmacokinetic interactions between treprostinil" preferredWord="Treprostinil" semType="eico, phsu"/><RxNorm RxCui="343048"/></Normalization></entity><entity charOffset="97:109" id="Dailymed.6c80bb38-e8db-4138-9f0d-dbbf9c673185.s.83.e.3" text="treprostinil" type="Biomedical_Entity"><Normalization><mmtx cui="C1145760" phraseText="an oral formulation of treprostinil" preferredWord="Treprostinil" semType="eico, phsu"/><RxNorm RxCui="343048"/></Normalization></entity><entity charOffset="198:206" id="Dailymed.6c80bb38-e8db-4138-9f0d-dbbf9c673185.s.83.e.4" text="bosentan" type="Biomedical_Entity"><Normalization><mmtx cui="C0252643" phraseText="bosentan" preferredWord="bosentan" semType="phsu, orch"/><RxNorm RxCui="75207"/></Normalization></entity><entity charOffset="124:138" id="Dailymed.6c80bb38-e8db-4138-9f0d-dbbf9c673185.s.83.e.5" text="diethanolamine" type="Biomedical_Entity"><Normalization><mmtx cui="C0057919" phraseText="(treprostinil diethanolamine" preferredWord="diethanolamine" semType="phsu, orch"/><RxNorm RxCui="1362911"/></Normalization></entity><pair ddi="false" e1="Dailymed.6c80bb38-e8db-4138-9f0d-dbbf9c673185.s.83.e.0" e2="Dailymed.6c80bb38-e8db-4138-9f0d-dbbf9c673185.s.83.e.1"/><pair ddi="false" e1="Dailymed.6c80bb38-e8db-4138-9f0d-dbbf9c673185.s.83.e.0" e2="Dailymed.6c80bb38-e8db-4138-9f0d-dbbf9c673185.s.83.e.2"/><pair ddi="false" e1="Dailymed.6c80bb38-e8db-4138-9f0d-dbbf9c673185.s.83.e.0" e2="Dailymed.6c80bb38-e8db-4138-9f0d-dbbf9c673185.s.83.e.3"/><pair ddi="false" e1="Dailymed.6c80bb38-e8db-4138-9f0d-dbbf9c673185.s.83.e.0" e2="Dailymed.6c80bb38-e8db-4138-9f0d-dbbf9c673185.s.83.e.5"/><pair ddi="false" e1="Dailymed.6c80bb38-e8db-4138-9f0d-dbbf9c673185.s.83.e.1" e2="Dailymed.6c80bb38-e8db-4138-9f0d-dbbf9c673185.s.83.e.4"/><pair ddi="false" e1="Dailymed.6c80bb38-e8db-4138-9f0d-dbbf9c673185.s.83.e.1" e2="Dailymed.6c80bb38-e8db-4138-9f0d-dbbf9c673185.s.83.e.5"/><pair ddi="false" e1="Dailymed.6c80bb38-e8db-4138-9f0d-dbbf9c673185.s.83.e.2" e2="Dailymed.6c80bb38-e8db-4138-9f0d-dbbf9c673185.s.83.e.4"/><pair ddi="false" e1="Dailymed.6c80bb38-e8db-4138-9f0d-dbbf9c673185.s.83.e.5" e2="Dailymed.6c80bb38-e8db-4138-9f0d-dbbf9c673185.s.83.e.2"/><pair ddi="false" e1="Dailymed.6c80bb38-e8db-4138-9f0d-dbbf9c673185.s.83.e.3" e2="Dailymed.6c80bb38-e8db-4138-9f0d-dbbf9c673185.s.83.e.4"/><pair ddi="false" e1="Dailymed.6c80bb38-e8db-4138-9f0d-dbbf9c673185.s.83.e.3" e2="Dailymed.6c80bb38-e8db-4138-9f0d-dbbf9c673185.s.83.e.5"/><pair ddi="false" e1="Dailymed.6c80bb38-e8db-4138-9f0d-dbbf9c673185.s.83.e.5" e2="Dailymed.6c80bb38-e8db-4138-9f0d-dbbf9c673185.s.83.e.4"/></sentence><sentence id="Dailymed.6c80bb38-e8db-4138-9f0d-dbbf9c673185.s.85" text="In a human pharmacokinetic study conducted with sildenafil (60 mg/day) and an oral formulation of treprostinil (treprostinil diethanolamine), no pharmacokinetic interactions between treprostinil and sildenafil were observed." type="negative"><entity charOffset="112:124" id="Dailymed.6c80bb38-e8db-4138-9f0d-dbbf9c673185.s.85.e.0" text="treprostinil" type="Biomedical_Entity"><Normalization><mmtx cui="C1145760" phraseText="(treprostinil diethanolamine" preferredWord="Treprostinil" semType="eico, phsu"/><RxNorm RxCui="343048"/></Normalization></entity><entity charOffset="98:110" id="Dailymed.6c80bb38-e8db-4138-9f0d-dbbf9c673185.s.85.e.1" text="treprostinil" type="Biomedical_Entity"><Normalization><mmtx cui="C1145760" phraseText="an oral formulation of treprostinil" preferredWord="Treprostinil" semType="eico, phsu"/><RxNorm RxCui="343048"/></Normalization></entity><entity charOffset="125:139" id="Dailymed.6c80bb38-e8db-4138-9f0d-dbbf9c673185.s.85.e.2" text="diethanolamine" type="Biomedical_Entity"><Normalization><mmtx cui="C0057919" phraseText="(treprostinil diethanolamine" preferredWord="diethanolamine" semType="phsu, orch"/><RxNorm RxCui="1362911"/></Normalization></entity><entity charOffset="182:194" id="Dailymed.6c80bb38-e8db-4138-9f0d-dbbf9c673185.s.85.e.3" text="treprostinil" type="Biomedical_Entity"><Normalization><mmtx cui="C1145760" phraseText="no pharmacokinetic interactions between treprostinil" preferredWord="Treprostinil" semType="eico, phsu"/><RxNorm RxCui="343048"/></Normalization></entity><entity charOffset="199:209" id="Dailymed.6c80bb38-e8db-4138-9f0d-dbbf9c673185.s.85.e.4" text="sildenafil" type="Biomedical_Entity"><Normalization><mmtx cui="C0529793" phraseText="sildenafil" preferredWord="sildenafil" semType="phsu, orch"/><RxNorm RxCui="136411"/></Normalization></entity><entity charOffset="48:58" id="Dailymed.6c80bb38-e8db-4138-9f0d-dbbf9c673185.s.85.e.5" text="sildenafil" type="Biomedical_Entity"><Normalization><mmtx cui="C0529793" phraseText="conducted with sildenafil" preferredWord="sildenafil" semType="phsu, orch"/><RxNorm RxCui="136411"/></Normalization></entity><pair ddi="false" e1="Dailymed.6c80bb38-e8db-4138-9f0d-dbbf9c673185.s.85.e.0" e2="Dailymed.6c80bb38-e8db-4138-9f0d-dbbf9c673185.s.85.e.2"/><pair ddi="false" e1="Dailymed.6c80bb38-e8db-4138-9f0d-dbbf9c673185.s.85.e.0" e2="Dailymed.6c80bb38-e8db-4138-9f0d-dbbf9c673185.s.85.e.4"/><pair ddi="false" e1="Dailymed.6c80bb38-e8db-4138-9f0d-dbbf9c673185.s.85.e.5" e2="Dailymed.6c80bb38-e8db-4138-9f0d-dbbf9c673185.s.85.e.0"/><pair ddi="false" e1="Dailymed.6c80bb38-e8db-4138-9f0d-dbbf9c673185.s.85.e.1" e2="Dailymed.6c80bb38-e8db-4138-9f0d-dbbf9c673185.s.85.e.2"/><pair ddi="false" e1="Dailymed.6c80bb38-e8db-4138-9f0d-dbbf9c673185.s.85.e.1" e2="Dailymed.6c80bb38-e8db-4138-9f0d-dbbf9c673185.s.85.e.4"/><pair ddi="false" e1="Dailymed.6c80bb38-e8db-4138-9f0d-dbbf9c673185.s.85.e.5" e2="Dailymed.6c80bb38-e8db-4138-9f0d-dbbf9c673185.s.85.e.1"/><pair ddi="false" e1="Dailymed.6c80bb38-e8db-4138-9f0d-dbbf9c673185.s.85.e.2" e2="Dailymed.6c80bb38-e8db-4138-9f0d-dbbf9c673185.s.85.e.3"/><pair ddi="false" e1="Dailymed.6c80bb38-e8db-4138-9f0d-dbbf9c673185.s.85.e.2" e2="Dailymed.6c80bb38-e8db-4138-9f0d-dbbf9c673185.s.85.e.4"/><pair ddi="false" e1="Dailymed.6c80bb38-e8db-4138-9f0d-dbbf9c673185.s.85.e.5" e2="Dailymed.6c80bb38-e8db-4138-9f0d-dbbf9c673185.s.85.e.2"/><pair ddi="false" e1="Dailymed.6c80bb38-e8db-4138-9f0d-dbbf9c673185.s.85.e.3" e2="Dailymed.6c80bb38-e8db-4138-9f0d-dbbf9c673185.s.85.e.4"/><pair ddi="false" e1="Dailymed.6c80bb38-e8db-4138-9f0d-dbbf9c673185.s.85.e.5" e2="Dailymed.6c80bb38-e8db-4138-9f0d-dbbf9c673185.s.85.e.3"/></sentence><sentence id="Dailymed.6c80bb38-e8db-4138-9f0d-dbbf9c673185.s.87" text="In vitro studies of human hepatic microsomes showed that treprostinil does not inhibit cytochrome P450 (CYP) isoenzymes CYP1A2, CYP2A6, CYP2C8, CYP2C9, CYP2C19, CYP2D6, CYP2E1 and CYP3A. " type="negative"><entity charOffset="109:119" id="Dailymed.6c80bb38-e8db-4138-9f0d-dbbf9c673185.s.87.e.0" text="isoenzymes" type="Biomedical_Entity"><Normalization><mmtx cui="C1442929" phraseText="cytochrome P450 (CYP) isoenzymes CYP1A2," preferredWord="Clinically relevant isoenzyme" semType="phsu, aapp, enzy"/><RxNorm RxCui="6021"/></Normalization></entity><entity charOffset="57:69" id="Dailymed.6c80bb38-e8db-4138-9f0d-dbbf9c673185.s.87.e.1" text="treprostinil" type="Biomedical_Entity"><Normalization><mmtx cui="C1145760" phraseText="that treprostinil" preferredWord="Treprostinil" semType="eico, phsu"/><RxNorm RxCui="343048"/></Normalization></entity><pair ddi="false" e1="Dailymed.6c80bb38-e8db-4138-9f0d-dbbf9c673185.s.87.e.1" e2="Dailymed.6c80bb38-e8db-4138-9f0d-dbbf9c673185.s.87.e.0"/></sentence><sentence id="Dailymed.6c80bb38-e8db-4138-9f0d-dbbf9c673185.s.88" text="Additionally, treprostinil does not induce cytochrome P450 isoenzymes CYP1A2, CYP2B6, CYP2C9, CYP2C19, and CYP3A. " type="negative"><entity charOffset="59:69" id="Dailymed.6c80bb38-e8db-4138-9f0d-dbbf9c673185.s.88.e.0" text="isoenzymes" type="Biomedical_Entity"><Normalization><mmtx cui="C1442929" phraseText="cytochrome P450 isoenzymes CYP1A2," preferredWord="Clinically relevant isoenzyme" semType="phsu, aapp, enzy"/><RxNorm RxCui="6021"/></Normalization></entity><entity charOffset="14:26" id="Dailymed.6c80bb38-e8db-4138-9f0d-dbbf9c673185.s.88.e.1" text="treprostinil" type="Biomedical_Entity"><Normalization><mmtx cui="C1145760" phraseText="treprostinil" preferredWord="Treprostinil" semType="eico, phsu"/><RxNorm RxCui="343048"/></Normalization></entity><pair ddi="false" e1="Dailymed.6c80bb38-e8db-4138-9f0d-dbbf9c673185.s.88.e.1" e2="Dailymed.6c80bb38-e8db-4138-9f0d-dbbf9c673185.s.88.e.0"/></sentence><sentence biomedicalEntities="4" id="Dailymed.6c80bb38-e8db-4138-9f0d-dbbf9c673185.s.91" lineNumber="115" text="Human pharmacokinetic studies with an oral formulation of treprostinil (treprostinil diethanolamine) indicated that co-administration of the cytochrome P450 (CYP) 2C8 enzyme inhibitor gemfibrozil increases exposure (both Cmax and AUC) to treprostinil. " type="regular"><anaphoraRelation><anaphoraEntity charOffset="238:250" id="Dailymed.6c80bb38-e8db-4138-9f0d-dbbf9c673185.s.91.e.4" text="treprostinil" type="Drug"/><antecedentEntity charOffset="72-99" id="Dailymed.6c80bb38-e8db-4138-9f0d-dbbf9c673185.s.91.e.0" text="treprostinil diethanolamine" type="Drug"/></anaphoraRelation><entity charOffset="72:99" id="Dailymed.6c80bb38-e8db-4138-9f0d-dbbf9c673185.s.91.e.0" text="treprostinil diethanolamine" type="Drug"><Normalization><mmtx cui="C1145760" phraseText="(treprostinil diethanolamine" preferredWord="Treprostinil" semType="eico, phsu"/><mmtx cui="C0057919" phraseText="(treprostinil diethanolamine" preferredWord="diethanolamine" semType="phsu, orch"/><RxNorm RxCui="343048"/></Normalization></entity><entity charOffset="141:183" id="Dailymed.6c80bb38-e8db-4138-9f0d-dbbf9c673185.s.91.e.1" text="cytochrome P450 (CYP) 2C8 enzyme inhibitor" type="Drug_Class"><Normalization><mmtx cui="C0014432" phraseText="that co-administration of the cytochrome P450 (CYP) 2C8 enzyme inhibitor gemfibrozil" preferredWord="Enzyme Inhibitors" semType="phsu"/><mmtx cui="C0919438" phraseText="that co-administration of the cytochrome P450 (CYP) 2C8 enzyme inhibitor gemfibrozil" preferredWord="Enzyme Inhibitor Drugs" semType="phsu"/><RxNorm RxCui="3065"/></Normalization></entity><entity charOffset="184:195" id="Dailymed.6c80bb38-e8db-4138-9f0d-dbbf9c673185.s.91.e.2" text="gemfibrozil" type="Drug"><Normalization><mmtx cui="C0017245" phraseText="that co-administration of the cytochrome P450 (CYP) 2C8 enzyme inhibitor gemfibrozil" preferredWord="Gemfibrozil" semType="phsu, lipd"/><mmtx cui="C0017245" phraseText="that co-administration of the cytochrome P450 (CYP) 2C8 enzyme inhibitor gemfibrozil" preferredWord="Gemfibrozil" semType="phsu, lipd"/><RxNorm RxCui="4719"/></Normalization></entity><entity charOffset="238:250" id="Dailymed.6c80bb38-e8db-4138-9f0d-dbbf9c673185.s.91.e.4" text="treprostinil" type="Drug"><Normalization><mmtx cui="C1145760" phraseText="AUC) to treprostinil." preferredWord="Treprostinil" semType="eico, phsu"/><RxNorm RxCui="343048"/></Normalization></entity><entity charOffset="196:214|221:225" id="Dailymed.6c80bb38-e8db-4138-9f0d-dbbf9c673185.s.91.e.5" text="increases exposure Cmax" type="Increase_Interaction"/><entity charOffset="196:214|230:233" id="Dailymed.6c80bb38-e8db-4138-9f0d-dbbf9c673185.s.91.e.8" text="increases exposure AUC" type="Increase_Interaction"/><drugClassMembership drug="Dailymed.6c80bb38-e8db-4138-9f0d-dbbf9c673185.s.91.e.2" drugClass="Dailymed.6c80bb38-e8db-4138-9f0d-dbbf9c673185.s.91.e.1"/><drugInteraction id="Dailymed.6c80bb38-e8db-4138-9f0d-dbbf9c673185.s.91.ddi.1"><interaction trigger="Dailymed.6c80bb38-e8db-4138-9f0d-dbbf9c673185.s.91.e.5"><relations><relation type="hasPrecipitant"><entity id="Dailymed.6c80bb38-e8db-4138-9f0d-dbbf9c673185.s.91.e.2"/></relation><relation type="hasObject"><entity id="Dailymed.6c80bb38-e8db-4138-9f0d-dbbf9c673185.s.91.e.4"/></relation></relations></interaction></drugInteraction><drugInteraction id="Dailymed.6c80bb38-e8db-4138-9f0d-dbbf9c673185.s.91.ddi.2"><interaction trigger="Dailymed.6c80bb38-e8db-4138-9f0d-dbbf9c673185.s.91.e.8"><relations><relation type="hasPrecipitant"><entity id="Dailymed.6c80bb38-e8db-4138-9f0d-dbbf9c673185.s.91.e.2"/></relation><relation type="hasObject"><entity id="Dailymed.6c80bb38-e8db-4138-9f0d-dbbf9c673185.s.91.e.4"/></relation></relations></interaction></drugInteraction><pair ddi="true" e1="Dailymed.6c80bb38-e8db-4138-9f0d-dbbf9c673185.s.91.e.2" e2="Dailymed.6c80bb38-e8db-4138-9f0d-dbbf9c673185.s.91.e.4" trigger="Dailymed.6c80bb38-e8db-4138-9f0d-dbbf9c673185.s.91.e.5" type="Increase_Interaction"/></sentence><sentence biomedicalEntities="3" id="Dailymed.6c80bb38-e8db-4138-9f0d-dbbf9c673185.s.92" lineNumber="115" text="Co-administration of the CYP2C8 enzyme inducer rifampin decreases exposure to treprostinil. " type="regular"><entity charOffset="25:46" id="Dailymed.6c80bb38-e8db-4138-9f0d-dbbf9c673185.s.92.e.0" text="CYP2C8 enzyme inducer" type="Drug_Class"><Normalization><RxNorm RxCui="687277"/></Normalization></entity><entity charOffset="47:55" id="Dailymed.6c80bb38-e8db-4138-9f0d-dbbf9c673185.s.92.e.1" text="rifampin" type="Drug"><Normalization><mmtx cui="C0035608" phraseText="Co-administration of the CYP2C8 enzyme inducer rifampin" preferredWord="Rifampin" semType="orch, antb"/><RxNorm RxCui="9384"/></Normalization></entity><entity charOffset="78:90" id="Dailymed.6c80bb38-e8db-4138-9f0d-dbbf9c673185.s.92.e.3" text="treprostinil" type="Drug"><Normalization><mmtx cui="C1145760" phraseText="exposure to treprostinil." preferredWord="Treprostinil" semType="eico, phsu"/><RxNorm RxCui="343048"/></Normalization></entity><entity charOffset="56:74" id="Dailymed.6c80bb38-e8db-4138-9f0d-dbbf9c673185.s.92.e.4" text="decreases exposure" type="Decrease_Interaction"/><drugClassMembership drug="Dailymed.6c80bb38-e8db-4138-9f0d-dbbf9c673185.s.92.e.1" drugClass="Dailymed.6c80bb38-e8db-4138-9f0d-dbbf9c673185.s.92.e.0"/><drugInteraction id="Dailymed.6c80bb38-e8db-4138-9f0d-dbbf9c673185.s.92.ddi.1"><interaction trigger="Dailymed.6c80bb38-e8db-4138-9f0d-dbbf9c673185.s.92.e.4"><relations><relation type="hasPrecipitant"><entity id="Dailymed.6c80bb38-e8db-4138-9f0d-dbbf9c673185.s.92.e.1"/></relation><relation type="hasObject"><entity id="Dailymed.6c80bb38-e8db-4138-9f0d-dbbf9c673185.s.92.e.3"/></relation></relations></interaction></drugInteraction><pair ddi="true" e1="Dailymed.6c80bb38-e8db-4138-9f0d-dbbf9c673185.s.92.e.1" e2="Dailymed.6c80bb38-e8db-4138-9f0d-dbbf9c673185.s.92.e.3" trigger="Dailymed.6c80bb38-e8db-4138-9f0d-dbbf9c673185.s.92.e.4" type="Decrease_Interaction"/></sentence><sentence id="Dailymed.6c80bb38-e8db-4138-9f0d-dbbf9c673185.s.94" text="Remodulin has not been studied in conjunction with Flolan or Tracleer  (bosentan)." type="negative"><entity charOffset="51:57" id="Dailymed.6c80bb38-e8db-4138-9f0d-dbbf9c673185.s.94.e.0" text="flolan" type="Biomedical_Entity"><Normalization><mmtx cui="C0376357" phraseText="studied in conjunction with Flolan" preferredWord="Flolan" semType="eico, phsu"/><RxNorm RxCui="114221"/></Normalization></entity><entity charOffset="72:80" id="Dailymed.6c80bb38-e8db-4138-9f0d-dbbf9c673185.s.94.e.1" text="bosentan" type="Biomedical_Entity"><Normalization><mmtx cui="C0252643" phraseText="(bosentan" preferredWord="bosentan" semType="phsu, orch"/><RxNorm RxCui="75207"/></Normalization></entity><entity charOffset="61:69" id="Dailymed.6c80bb38-e8db-4138-9f0d-dbbf9c673185.s.94.e.2" text="tracleer" type="Biomedical_Entity"><Normalization><mmtx cui="C1101331" phraseText="Tracleer" preferredWord="Tracleer" semType="phsu, orch"/><RxNorm RxCui="323502"/></Normalization></entity><entity charOffset="0:9" id="Dailymed.6c80bb38-e8db-4138-9f0d-dbbf9c673185.s.94.e.3" text="remodulin" type="Biomedical_Entity"><Normalization><mmtx cui="C1101501" phraseText="Remodulin" preferredWord="Remodulin" semType="phsu, lipd"/><RxNorm RxCui="323640"/></Normalization></entity><pair ddi="false" e1="Dailymed.6c80bb38-e8db-4138-9f0d-dbbf9c673185.s.94.e.0" e2="Dailymed.6c80bb38-e8db-4138-9f0d-dbbf9c673185.s.94.e.1"/><pair ddi="false" e1="Dailymed.6c80bb38-e8db-4138-9f0d-dbbf9c673185.s.94.e.0" e2="Dailymed.6c80bb38-e8db-4138-9f0d-dbbf9c673185.s.94.e.2"/><pair ddi="false" e1="Dailymed.6c80bb38-e8db-4138-9f0d-dbbf9c673185.s.94.e.3" e2="Dailymed.6c80bb38-e8db-4138-9f0d-dbbf9c673185.s.94.e.0"/><pair ddi="false" e1="Dailymed.6c80bb38-e8db-4138-9f0d-dbbf9c673185.s.94.e.2" e2="Dailymed.6c80bb38-e8db-4138-9f0d-dbbf9c673185.s.94.e.1"/><pair ddi="false" e1="Dailymed.6c80bb38-e8db-4138-9f0d-dbbf9c673185.s.94.e.3" e2="Dailymed.6c80bb38-e8db-4138-9f0d-dbbf9c673185.s.94.e.1"/><pair ddi="false" e1="Dailymed.6c80bb38-e8db-4138-9f0d-dbbf9c673185.s.94.e.3" e2="Dailymed.6c80bb38-e8db-4138-9f0d-dbbf9c673185.s.94.e.2"/></sentence><sentence id="Dailymed.6c80bb38-e8db-4138-9f0d-dbbf9c673185.s.96" text="Drug interaction studies have been carried out with treprostinil (oral or subcutaneous) co-administered with acetaminophen (4 g/day), warfarin (25 mg/day), and fluconazole (200 mg/day), respectively in healthy volunteers. " type="negative"><entity charOffset="109:122" id="Dailymed.6c80bb38-e8db-4138-9f0d-dbbf9c673185.s.96.e.0" text="acetaminophen" type="Biomedical_Entity"><Normalization><mmtx cui="C2917659" phraseText="co-administered with acetaminophen" preferredWord="Acetaminophen [EPC]" semType="phsu"/><RxNorm RxCui="161"/></Normalization></entity><entity charOffset="134:142" id="Dailymed.6c80bb38-e8db-4138-9f0d-dbbf9c673185.s.96.e.1" text="warfarin" type="Biomedical_Entity"><Normalization><mmtx cui="C0043031" phraseText="warfarin" preferredWord="Warfarin" semType="phsu, orch, hops"/><RxNorm RxCui="11289"/></Normalization></entity><entity charOffset="160:171" id="Dailymed.6c80bb38-e8db-4138-9f0d-dbbf9c673185.s.96.e.2" text="fluconazole" type="Biomedical_Entity"><Normalization><mmtx cui="C0016277" phraseText="fluconazole" preferredWord="Fluconazole" semType="phsu, orch"/><RxNorm RxCui="4450"/></Normalization></entity><entity charOffset="52:64" id="Dailymed.6c80bb38-e8db-4138-9f0d-dbbf9c673185.s.96.e.3" text="treprostinil" type="Biomedical_Entity"><Normalization><mmtx cui="C1145760" phraseText="out with treprostinil" preferredWord="Treprostinil" semType="eico, phsu"/><RxNorm RxCui="343048"/></Normalization></entity><pair ddi="false" e1="Dailymed.6c80bb38-e8db-4138-9f0d-dbbf9c673185.s.96.e.0" e2="Dailymed.6c80bb38-e8db-4138-9f0d-dbbf9c673185.s.96.e.1"/><pair ddi="false" e1="Dailymed.6c80bb38-e8db-4138-9f0d-dbbf9c673185.s.96.e.0" e2="Dailymed.6c80bb38-e8db-4138-9f0d-dbbf9c673185.s.96.e.2"/><pair ddi="false" e1="Dailymed.6c80bb38-e8db-4138-9f0d-dbbf9c673185.s.96.e.3" e2="Dailymed.6c80bb38-e8db-4138-9f0d-dbbf9c673185.s.96.e.0"/><pair ddi="false" e1="Dailymed.6c80bb38-e8db-4138-9f0d-dbbf9c673185.s.96.e.1" e2="Dailymed.6c80bb38-e8db-4138-9f0d-dbbf9c673185.s.96.e.2"/><pair ddi="false" e1="Dailymed.6c80bb38-e8db-4138-9f0d-dbbf9c673185.s.96.e.3" e2="Dailymed.6c80bb38-e8db-4138-9f0d-dbbf9c673185.s.96.e.1"/><pair ddi="false" e1="Dailymed.6c80bb38-e8db-4138-9f0d-dbbf9c673185.s.96.e.3" e2="Dailymed.6c80bb38-e8db-4138-9f0d-dbbf9c673185.s.96.e.2"/></sentence><sentence id="Dailymed.6c80bb38-e8db-4138-9f0d-dbbf9c673185.s.98" text="Treprostinil does not affect the pharmacokinetics or pharmacodynamics of warfarin. " type="negative"><entity charOffset="73:81" id="Dailymed.6c80bb38-e8db-4138-9f0d-dbbf9c673185.s.98.e.0" text="warfarin" type="Biomedical_Entity"><Normalization><mmtx cui="C0043031" phraseText="pharmacodynamics of warfarin." preferredWord="Warfarin" semType="phsu, orch, hops"/><RxNorm RxCui="11289"/></Normalization></entity><entity charOffset="0:12" id="Dailymed.6c80bb38-e8db-4138-9f0d-dbbf9c673185.s.98.e.1" text="treprostinil" type="Biomedical_Entity"><Normalization><mmtx cui="C1145760" phraseText="Treprostinil" preferredWord="Treprostinil" semType="eico, phsu"/><RxNorm RxCui="343048"/></Normalization></entity><pair ddi="false" e1="Dailymed.6c80bb38-e8db-4138-9f0d-dbbf9c673185.s.98.e.1" e2="Dailymed.6c80bb38-e8db-4138-9f0d-dbbf9c673185.s.98.e.0"/></sentence><sentence id="Dailymed.6c80bb38-e8db-4138-9f0d-dbbf9c673185.s.99" text="The pharmacokinetics of R- and S- warfarin and the INR in healthy subjects given a single 25 mg dose of warfarin were unaffected by continuous subcutaneous infusion of treprostinil at an infusion rate of 10 ng/kg/min." type="negative"><entity charOffset="81:92" id="Dailymed.6c80bb38-e8db-4138-9f0d-dbbf9c673185.s.99.e.0" text="a 25" type="Biomedical_Entity"><Normalization><mmtx cui="C0718136" phraseText="a single 25 mg dose of warfarin" preferredWord="A-25" semType="phsu, orch, vita"/><RxNorm RxCui="NA"/></Normalization></entity><entity charOffset="104:112" id="Dailymed.6c80bb38-e8db-4138-9f0d-dbbf9c673185.s.99.e.1" text="warfarin" type="Biomedical_Entity"><Normalization><mmtx cui="C0043031" phraseText="a single 25 mg dose of warfarin" preferredWord="Warfarin" semType="phsu, orch, hops"/><RxNorm RxCui="11289"/></Normalization></entity><entity charOffset="168:180" id="Dailymed.6c80bb38-e8db-4138-9f0d-dbbf9c673185.s.99.e.2" text="treprostinil" type="Biomedical_Entity"><Normalization><mmtx cui="C1145760" phraseText="unaffected by continuous subcutaneous infusion of treprostinil" preferredWord="Treprostinil" semType="eico, phsu"/><RxNorm RxCui="343048"/></Normalization></entity><entity charOffset="34:42" id="Dailymed.6c80bb38-e8db-4138-9f0d-dbbf9c673185.s.99.e.3" text="warfarin" type="Biomedical_Entity"><Normalization><mmtx cui="C0043031" phraseText="warfarin" preferredWord="Warfarin" semType="phsu, orch, hops"/><RxNorm RxCui="11289"/></Normalization></entity><pair ddi="false" e1="Dailymed.6c80bb38-e8db-4138-9f0d-dbbf9c673185.s.99.e.0" e2="Dailymed.6c80bb38-e8db-4138-9f0d-dbbf9c673185.s.99.e.1"/><pair ddi="false" e1="Dailymed.6c80bb38-e8db-4138-9f0d-dbbf9c673185.s.99.e.0" e2="Dailymed.6c80bb38-e8db-4138-9f0d-dbbf9c673185.s.99.e.2"/><pair ddi="false" e1="Dailymed.6c80bb38-e8db-4138-9f0d-dbbf9c673185.s.99.e.3" e2="Dailymed.6c80bb38-e8db-4138-9f0d-dbbf9c673185.s.99.e.0"/><pair ddi="false" e1="Dailymed.6c80bb38-e8db-4138-9f0d-dbbf9c673185.s.99.e.1" e2="Dailymed.6c80bb38-e8db-4138-9f0d-dbbf9c673185.s.99.e.2"/><pair ddi="false" e1="Dailymed.6c80bb38-e8db-4138-9f0d-dbbf9c673185.s.99.e.3" e2="Dailymed.6c80bb38-e8db-4138-9f0d-dbbf9c673185.s.99.e.2"/></sentence><positiveExamples number="8"/><negativeExamples number="84"/></document>